Pure Global
NCT04563897

Prospective Multicenter Study on Clinical Application of Sonazoid in Liver Tumor

Contrast-enhanced Ultrasound in Liver Tumor by Sonazoid
Chinese PLA General Hospital·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ultrasound
Study type
Observational
Sponsor & location
Primary sponsor
Chinese PLA General Hospital
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2020
End date
Aug 01, 2021
Enrollment
1300 participants
Primary outcome

Diagnostic performance of contrast-enhanced ultrasound in different liver background and liver turmors by sonazoid

Summary

Sonazoid as a new generation of ultrasound contrast agent.This study based on the features of
 Sonazoid specific angiography and his mechanical index, the role of Sonazoidin in the
 differential diagnosis of benign and malignant focal liver lesions in different liver
 background was explored

ICD-10 classifications
Abnormal ultrasonic finding on antenatal screening of motherAntenatal screening for malformations using ultrasound and other physical methodsAntenatal screening for fetal growth retardation using ultrasound and other physical methodsOther diagnostic agentsExamination of ears and hearing
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04563897
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04563897 through Pure Global AI's free database. This phase not specified trial is sponsored by Chinese PLA General Hospital and is currently Not yet recruiting. The study focuses on Ultrasound. Target enrollment is 1300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.